{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T20:41:46Z","timestamp":1773866506356,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2006,4]]},"DOI":"10.1136\/ijgc-00009577-200605000-00033","type":"journal-article","created":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T12:28:03Z","timestamp":1551875283000},"page":"1165-1171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Phase II study of tirapazamine plus cisplatin in patients with advanced or recurrent cervical cancer"],"prefix":"10.1016","volume":"16","author":[{"given":"F.C.","family":"Maluf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.L.","family":"Leiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Aghajanian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Sabbatini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Pezzulli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.S.","family":"Chi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.K.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Levenback","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Loh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.R.","family":"Spriggs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-00009577-200605000-00033_bb0005","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1200\/JCO.2004.12.006","article-title":"Phase II study of cisplatin and vinorelbine in squamous cell carcinoma of the cervix: a gynecologic oncology group study","volume":"22","author":"Morris","year":"2004","journal-title":"J Clin Oncol"},{"issue":"Pt 2","key":"10.1136\/ijgc-00009577-200605000-00033_bb0010","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/S0090-8258(03)00465-7","article-title":"The role of topotecan in the treatment of advanced cervical cancer","volume":"90","author":"Fiorica","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-00009577-200605000-00033_bb0015","first-page":"397","volume":"92","author":"Long HJ","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-00009577-200605000-00033_bb0020","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1200\/JCO.1998.16.5.1879","article-title":"Chemotherapy for cervical carcinoma: factors determining response and implications for clinical trial design","volume":"16","author":"Brader","year":"1998","journal-title":"J Clin Oncol"},{"issue":"Suppl. 2","key":"10.1136\/ijgc-00009577-200605000-00033_bb0025","first-page":"43","article-title":"Carcinoma of the uterine cervix: current status and future directions","volume":"21","author":"Thigpen","year":"1994","journal-title":"Semin Oncol"},{"key":"10.1136\/ijgc-00009577-200605000-00033_bb0030","first-page":"5863","article-title":"The hypoxic cell: a target for selective cancer therapy\u2014 eighteenth Bruce F. Cain Memorial Award lecture","volume":"59","author":"Brown","year":"1999","journal-title":"Cancer Res"},{"key":"10.1136\/ijgc-00009577-200605000-00033_bb0035","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0360-3016(98)00302-2","article-title":"Bioreductive therapies: an overview of drugs and their mechanisms of action","volume":"42","author":"Rauth","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1136\/ijgc-00009577-200605000-00033_bb0040","first-page":"4633","article-title":"Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin","volume":"53","author":"Dorie","year":"1993","journal-title":"Cancer Res"},{"issue":"Suppl. 4","key":"10.1136\/ijgc-00009577-200605000-00033_bb0045","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/bjc.1998.430","article-title":"Exploiting tumour hypoxia and overcoming mutant p53 with tirapazamine","volume":"77","author":"Brown","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-00009577-200605000-00033_bb0050","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0167-8140(97)00224-7","article-title":"Potentiation of cisplatin activity by the bioreductive agent tirapazamine","volume":"47","author":"Siemann","year":"1998","journal-title":"Radiother Oncol"},{"key":"10.1136\/ijgc-00009577-200605000-00033_bb0055","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1200\/JCO.2000.18.6.1351","article-title":"Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors","volume":"18","author":"von Pawel","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-00009577-200605000-00033_bb0060","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.1997.15.2.773","article-title":"Phase I trial of tirapazamine in combination with cisplatin in a single dose every 3 weeks in patients with solid tumors","volume":"15","author":"Johnson","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-00009577-200605000-00033_bb0065","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1200\/JCO.2001.19.2.535","article-title":"Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer","volume":"19","author":"Rischin","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-00009577-200605000-00033_bb0070","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/00001813-199909000-00007","article-title":"Phase II trial of escalated dose of tirapazamine combined with cisplatin in advanced malignant melanoma","volume":"10","author":"Bedikian","year":"1999","journal-title":"Anticancer Drugs"},{"key":"10.1136\/ijgc-00009577-200605000-00033_bb0075","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1200\/JCO.2005.01.072","article-title":"Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02)","volume":"23","author":"Rischin","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-00009577-200605000-00033_bb0080","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0360-3016(00)00720-3","article-title":"A phase I\/II evaluation of tirapazamine administered intravenously concurrent with cisplatin and radiotherapy in women with locally advanced cervical cancer","volume":"48","author":"Craighead","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1136\/ijgc-00009577-200605000-00033_bb0085","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1200\/JCO.2000.18.6.1254","article-title":"Single-arm, open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme","volume":"18","author":"Del Rowe","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-00009577-200605000-00033_bb0090","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1006\/gyno.1997.4841","article-title":"Phase I study of tirapazamine and cisplatin in patients with recurrent cervical cancer","volume":"67","author":"Aghajanian","year":"1997","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-00009577-200605000-00033_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1136\/ijgc-00009577-200605000-00033_bb0100","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.critrevonc.2004.05.003","article-title":"The role of chemotherapy in locally advanced, metastatic and recurrent cervical cancer","volume":"52","author":"Tambaro","year":"2004","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1136\/ijgc-00009577-200605000-00033_bb0105","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1200\/JCO.1985.3.8.1079","article-title":"Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study","volume":"3","author":"Bonomi","year":"1985","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-00009577-200605000-00033_bb0110","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1006\/gyno.1999.5657","article-title":"A phase II study of gemcitabine and cisplatin in patients with advanced, persistent, or recurrent squamous cell carcinoma of the cervix","volume":"76","author":"Burnett","year":"2000","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-00009577-200605000-00033_bb0115","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00000421-199706000-00023","article-title":"The addition of bleomycin and dose-escalated ifosfamide to the combination of cisplatin plus ifosfamide does not improve survival in advanced or recurrent cervical carcinoma","volume":"20","author":"Hempling","year":"1997","journal-title":"Am J Clin Oncol"},{"key":"10.1136\/ijgc-00009577-200605000-00033_bb0120","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1200\/JCO.1997.15.1.165","article-title":"Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study","volume":"15","author":"Omura","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-00009577-200605000-00033_bb0125","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.1999.17.3.761","article-title":"Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix","volume":"17","author":"Papadimitirou","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-00009577-200605000-00033_bb0130","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1200\/JCO.1999.17.9.2676","article-title":"Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study","volume":"17","author":"Rose","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-00009577-200605000-00033_bb0135","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2004.04.170","article-title":"Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study","volume":"22","author":"Moore","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-00009577-200605000-00033_bb0140","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/bjc.1993.220","article-title":"SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours","volume":"67","author":"Brown","year":"1993","journal-title":"Br J Cancer"},{"issue":"Suppl. 4","key":"10.1136\/ijgc-00009577-200605000-00033_bb0145","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/bjc.1998.431","article-title":"Tirapazamine-cisplatin: the synergy","volume":"77","author":"Gatzemeier","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-00009577-200605000-00033_bb0150","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0090-8258(89)80033-2","article-title":"A randomized comparison of a rapid versus prolonged (24 hr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a gynecologic oncology group study","volume":"32","author":"Thigpen","year":"1989","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-00009577-200605000-00033_bb0155","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1023\/A:1008219125746","article-title":"Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer","volume":"8","author":"Miller","year":"1997","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-00009577-200605000-00033_bb0160","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.1200\/JCO.1998.16.11.3524","article-title":"Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: a phase II study","volume":"16","author":"Treat","year":"1998","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24033413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24033413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-00009577-200605000-00033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:16:45Z","timestamp":1753233405000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24033413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":32,"aliases":["10.1111\/j.1525-1438.2006.00454.x"],"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["S1048891X24033413"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-00009577-200605000-00033","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2006,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II study of tirapazamine plus cisplatin in patients with advanced or recurrent cervical cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-00009577-200605000-00033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright Copyright \u00a9 2006 Blackwell Publishing Ltd.","name":"copyright","label":"Copyright"}]}}